• IDL Diagnostics' Q3 loss after financial items narrowed 44% year over year to SEK 1.73 million.
• Net sales fell to SEK 11.06 million, while operating cash outflow narrowed 73% to SEK 1.59 million.
• CEO Gustav Sten said commercial initiatives were moving from market preparation toward launch, while the company continued expanding its geographic presence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDL Diagnostics AB (publ) published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.